Clinical Data Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 BioSpaceSales of Amgen's thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025. Clinical DataOphthalmologyRead full story Post navigation Previous: Amgen scores with new thyroid eye disease formulationNext: AI giant Anthropic buys Coefficient Bio for $400m Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
